Dose Response to Recombinant Factor VIIa When Administered for Bleed

Completed · Phase 1

Conditions studied: Congenital Bleeding Disorder, Healthy

In brief

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

Key facts

Study ID

NCT00104455

Run by

Novo Nordisk A/S

People needed

64

Starts

2004-06-01

Expected to finish

2004-11-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 60. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Ages Eligible for Study: 18 Years - 60 Years

You may not qualify if…

• - -

Where it is running

• Novo Nordisk Investigational Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.